Potential Emergency Off-Switch for Psychedelic Assisted Therapies BASEL, Switzerland, Feb. 17, 2021 /CNW/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced the start of a study for its LSD neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session. This discovery, when further developed…


Previous articleField Trip Health Ltd. Reports Third Fiscal Quarter 2021 Financial Results
Next articleMindMed’s LSD Neutralizer Study Begins